- '25e-'27e adj. EBITA down 5-3% - Weaker UK retail sales could impede EBITA growth - '25e EV/adj.
- Occupancy improvement in Q2 - Management open for more accretion - 2025e P/CEPS at 14x, ~12.
Prisma Properties, noterat i juni 2024, fokuserar på externa handelsplatser i trafiknära lägen med i...
Redeye is growing more optimistic about the investment case in Oncopeptides after two news items thi...
Finnair reports Q2 results on Jul 16. Industrial action has continued to affect performance, while t...
Redeye provides an initial take on Waystream’s Q2 numbers that were presented this morning, which ca...
Redeye comments on Carasent’s Q2 report, showing a more positive outlook than the preliminary figure...
Redeye comments on Invisio ahead of Q2-results (due 18 July) where we expect sequential improvement ...
Redeye lifts its ARR and EBITDA-CAPEX estimates for Litium after the Q2 report, where ARR growth sig...
Redeye publishes a preview of Transtema’s Q2 report.
- Q2 report Tuesday, 18 April at 08:30 CET - '25e-'27e adj.
Redeye positively views yesterday’s press release from Acarix announcing that it has secured its fir...
Coor förväntas redovisa en något lägre omsättning, men förbättrade marginaler tack vare lägre person...
Redeye comments on Litium’s Q2 report, returning to a solid ARR growth of 12%.
- Q2 report due Monday, 14 July - Adj. EBITA by 6-5% on '25e-'27e; 5% CAGR '24-'27e - Trading at 12-...
- SEK 72m follow-up order (Terminals) from Swedish FMV - Deliveries start in Q3 - Could add ~10% to ...
Active Biotech har tagit ett steg närmre ett partnerskap i och med slutförandet av LION-studien.
The company sells its Marine and Offshore Unit for EUR 7.
Redeye comments on Carasent’s preliminary Q2 figures, the revised 2025 targets, and the new mid-term...
Redeye comments on Isofol’s recently announced rights issue outcome.
